(917) 310-3371
Gonorrhea treatment starts with the infection site, symptoms and any complications. Urogenital, throat and rectal infections do not share every treatment option.
Ask about the evaluation, genital and exposed-site tests, other STI tests, medication and any injection administration. Additional chlamydia treatment or a test of cure can create separate charges. Confirm whether the proposed drug is suitable and covered under your exact plan and whether the pharmacy or administration site can supply it. New oral approval does not guarantee lower total cost or Nao stock. If a chosen medication is delayed, contact the clinician about an available appropriate regimen. A positive result needs a treatment and partner plan, not only a price comparison.
Gonorrhea treatment starts with the infection site, symptoms and any complications. Urogenital, throat and rectal infections do not share every treatment option. Many people have no symptoms, so a partner’s diagnosis or screening result can still require care. New oral medicines add choices for eligible uncomplicated urogenital infection, while ceftriaxone remains the standard regimen in the current CDC guideline. Your plan should also cover other infections, partners and follow-up.
People with a positive result, a diagnosed partner exposure or compatible symptoms need clinical assessment. Tell the clinician about oral and anal exposures so throat and rectal infections are not missed. Blujepa’s gonorrhea label applies from age 12 and 45 kg, with limited or no alternatives; Nuzolvence applies from age 12 and 35 kg. Both approvals are for uncomplicated urogenital disease. A younger child, pregnancy, pelvic inflammatory disease, epididymitis or disseminated infection needs an appropriate separate pathway.
Bring the complete laboratory report rather than only a notification. The clinician reviews sampled sites, prior treatment and partner information and checks for complications.
Current CDC guidance uses ceftriaxone injection as standard treatment. The December 2025 oral approvals have product-specific eligibility and safety checks. Approval is not a reason to use an oral drug for an unlabeled site or ignore interactions.
If chlamydia has not been excluded, the clinician determines whether additional treatment is needed. HIV, syphilis and other testing may be appropriate. Discuss pregnancy prevention, vaccination and HIV prevention based on your situation.
Sex partners need evaluation and treatment. Avoid sex for seven days after treatment and until partners have been treated and symptoms have resolved. Get a written retesting and symptom-contact plan.
Bring medication allergies, the drugs and supplements you take, pregnancy possibility and previous antibiotic treatment. Tell the service if you cannot receive an injection, swallow tablets or return for follow-up. Those are useful planning issues, but they do not establish that a specific oral product is safe for you. Ask whether the prescribed medicine treats every positive site and what happens if another test becomes positive later.
Seek urgent assessment for fever with severe pelvic or abdominal pain, significant testicular pain, eye symptoms or a painful swollen joint. Persistent symptoms after treatment may reflect reinfection, another diagnosis or treatment failure and can require culture and susceptibility testing. Do not repeatedly treat yourself with leftover antibiotics. A severe allergic reaction needs emergency care.
CDC recommends test of cure 7–14 days after treatment for pharyngeal gonorrhea. Routine test of cure is not needed for uncomplicated urogenital or rectal infections treated with recommended regimens, but new-drug or other clinical circumstances may require a specific plan. Retesting about three months later looks for reinfection and serves a different purpose. Ask which test you need and when.
Confirm evaluation, site-specific testing, the medication and any administration charge. A single price for ‘gonorrhea care’ may omit the visit, lab, additional infection treatment or follow-up. Confirm the actual quote, supply and approval for the chosen regimen. If you have symptoms or a diagnosed exposure, request prompt evaluation and an available appropriate regimen while financial details are checked.
No. A benefits estimate, an accepted insurance name or approval for one service does not guarantee payment for the entire care plan. Verify the exact plan, treating clinician and site, service codes, referral/authorization requirements, medication benefit and separate laboratory or administration charges. Ask for the written decision and expected personal cost before a nonurgent visit.
Have your insurance card ready when booking. Share member details through the clinic’s confirmed secure intake process. Check with the clinic and your insurer that the exact plan covers the clinician and requested service. Ask about visit charges, any separately billed tests or medicines, and any referral or authorization requirement. Coverage and your copay or deductible depend on the plan; request a written estimate if paying yourself.
Do not assume the medicine, laboratory work, administration, monitoring or follow-up is included in the evaluation fee. Ask for an itemized estimate and identify which charges go to the clinic, pharmacy or laboratory. An approved appointment benefit and an approved medication benefit can be separate decisions.
Choose the right appointment type to continue.
